ENGLEWOOD, CO --(Marketwired - October 17, 2017) - Viveve Medical, Inc. (
"We are very pleased to receive regulatory approval in Mexico for our clinically-proven device that delivers the GENEVEVE™ treatment to improve sexual function. Mexico is one of the largest markets for women's health in Latin America and represents the continued advancement of our global commercialization strategy. Viveve has received regulatory clearances in nine new markets year-to-date," said Patricia Scheller, chief executive officer of Viveve. "Vitre-Tech, our distinguished distribution partner in this market, can now provide clinicians with a safe and effective 30-minute single-session treatment option for their patients who suffer from vaginal introital laxity, a condition that can profoundly affect a woman's sexual satisfaction and overall quality of life."
Regulatory approvals and clearances for the Viveve System for treatment of vaginal laxity or improvement in sexual function have been received from more than 50 countries. Viveve is also working to submit an investigational device exemption (IDE) to the U.S. Food and Drug Administration (FDA) to conduct a pivotal study on the use of the Viveve System for improvement in sexual function in women.
About Viveve Viveve Medical, Inc. is a women's health and wellness company passionately committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System, that delivers the GENEVEVE™ treatment, incorporates clinically-proven cryogen-cooled, monopolar radiofrequency (CMRF) energy-based technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate robust neocollagenesis in one 30-minute in-office session.
InControl Products by Viveve are FDA cleared medical devices that treat stress, urge, and mixed incontinence conditions and products to improve pelvic floor strength. Viveve exclusively distributes InControl Medical's products to healthcare providers in the United States. For more information visit Viveve's website at www.viveve.com .
Safe Harbor Statement All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. While management has based any forward-looking statements included in this press release on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties and other factors, many of which are outside of our control, which could cause actual results to materially differ from such statements. Such risks, uncertainties and other factors include, but are not limited to, the fluctuation of global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic and current reports available for review at www.sec.gov . Furthermore, we operate in a highly competitive and rapidly changing environment where new and unanticipated risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. We disclaim any intention to, and undertake no obligation to, update or revise forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Viveve is a registered trademark of Viveve, Inc. Geneveve is a trademark of Viveve, Inc.
Investor Relations contacts: Sarah McCabe Stern Investor Relations, Inc. 1270 Avenue of the Americas, Suite 408 New York, NY 10020 (212) 362-1200 sarah@sternir.com Amato and Partners, LLC Investor Relations Counsel New York, NY admin@amatoandpartners.com Media contact: Sara Zelkovic Berry & Company Public Relations (212) 253-8881 szelkovic@berrypr.com
